Please ensure Javascript is enabled for purposes of website accessibility

Canopy Growth Buys Out Cannabis Research Joint Venture

By Eric Volkman – Aug 9, 2019 at 10:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ambitious marijuana company continues to strengthen its medical cannabis business.

The acquisition streak in the marijuana industry just got a bit longer. Canadian producer Canopy Growth (CGC 5.68%) announced it has reached a deal to fully acquire a research joint venture it co-founded in 2018.

That business is Beckley Canopy Therapeutics, described by Canopy Growth as an entity designed "to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection." Canopy Growth disclosed neither the terms nor the price of its acquisition.

A hand holding a bottle and dropper filled with oil with marijuana plants in the background.

Image source: Getty Images.

With the deal, Canopy Growth will also become the full owner of Spectrum Biomedical UK, an entity formed to distribute the company's medicinal cannabis products. Currently, Spectrum Biomedical UK is a joint venture between Canopy Growth and Beckley Canopy Therapeutics that was formed in January.

As for the core asset of the acquisition, Beckley Canopy Therapeutics will be fused with Canopy Growth's in-house research program. The aim, said Canopy Growth, is "to combine the best teams, programs and clinical work all under a single strategic plan."

Canopy Growth co-founded Beckley Canopy in early 2018 with U.K.-based think tank Beckley Research & Innovations. According to Canopy Growth, the joint venture's research has advanced understanding in three areas of pharmaceutical research: cancer pain, opioid sparing, and smoking cessation. Such projects are ongoing.

The buyout of the joint venture is the latest in a string of acquisitions made by Canopy Growth. Recently the company has focused on bulking up its portfolio in the medical cannabis field. As part of this strategy, in May it bought Germany's C3, a producer, distributor, and researcher of cannabinoid-based medications targeting the European market.

Canopy Growth also aims to have a global presence for its various products; it has focused on Europe in particular as an appropriate market. It believes that countries on the continent are evolving in the areas of public policy and patient access to medical marijuana and related products.

Canopy Growth's purchase of the portion of Beckley Canopy Therapeutics it didn't own already is subject to approval from the relevant regulatory bodies. The acquisition is expected to close within the next 60 days.

The company's shares did not move significantly on the news. On Friday, they closed up in price only marginally.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.88 (5.68%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.